<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>TC chemotherapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/tc-chemotherapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 04 Oct 2026 16:03:32 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.2</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>TC chemotherapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Adding Immunotherapy to Chemo and Bevacizumab Extends Survival in Recurrent Cervical Cancer</title>
		<link>https://bioengineer.org/adding-immunotherapy-to-chemo-and-bevacizumab-extends-survival-in-recurrent-cervical-cancer/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sun, 04 Oct 2026 16:03:32 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[bevacizumab]]></category>
		<category><![CDATA[carboplatin]]></category>
		<category><![CDATA[Cervical cancer]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[overall survival]]></category>
		<category><![CDATA[paclitaxel]]></category>
		<category><![CDATA[PD-1 inhibitor]]></category>
		<category><![CDATA[progression-free survival]]></category>
		<category><![CDATA[recurrent cancer]]></category>
		<category><![CDATA[T-cell subsets]]></category>
		<category><![CDATA[TC chemotherapy]]></category>
		<category><![CDATA[tislelizumab]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=401134</guid>

					<description><![CDATA[A retrospective Chinese study finds that adding the PD-1 inhibitor tislelizumab to paclitaxel-carboplatin chemotherapy and bevacizumab significantly improves response rates, immune markers, and survival in recurrent cervical cancer.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">401134</post-id>	</item>
	</channel>
</rss>
